Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
USA: A first-in-class triple hormone receptor agonist, retatrutide, has demonstrated striking reductions in body weight along ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eggoz Cancer Controversy Explained: Should You Really Worry and What Type of Eggs You Should Eat Now - ...
News Quiz for Dec. 13, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback